Hydroxymethylation of Quinolines with Na<sub>2</sub>
S<sub>2</sub>
O<sub>8</sub>
by a Radical Pathway
作者:Luan Zhou、Naoki Okugawa、Hideo Togo
DOI:10.1002/ejoc.201701321
日期:2017.11.9
Treatment of quinolines bearing methyl, fluoro, chloro, bromo, acetyl, methoxycarbonyl, trifluoromethyl, or cyano groups with Na2S2O8 in a mixture of methanol and water at 70 °C for 4 h gave the corresponding hydroxymethylated compounds in good to moderate yields. The hydroxymethyl group of the product was transformed into aldehyde, ester, amide, aminomethyl, cyano, and tetrazole groups.
在甲醇和水的混合物中,用Na 2 S 2 O 8在70°C下处理带有甲基,氟,氯,溴,乙酰基,甲氧基羰基,三氟甲基或氰基的喹啉4小时,得到相应的羟甲基化化合物中等产量。产物的羟甲基被转化为醛,酯,酰胺,氨甲基,氰基和四唑基。
The Ag-promoted α-C–H arylation of alcohols
作者:Shoufeng Wang、Shuya Xing、Yingying Zhang、Yafei Fan、Huaiqing Zhao、Jianfeng Wang、Shuxiang Zhang、Wengui Wang
DOI:10.1039/c9ra09954a
日期:——
We herein report the functionalization of α-C–H in alcohols through cross-dehydrogenative coupling reactions.
我们在此报告了通过交叉脱氢偶联反应在醇中的α-C-H上进行的官能化。
Reverse hydroxamic acid derivatives
申请人:——
公开号:US20040242928A1
公开(公告)日:2004-12-02
Reverse hydroxamic acid derivatives having specific structure represented by a general formula (Ia):
1
(wherein A is a hydrogen atom or the like; Ar
1
is an arylene or the like; Ar
2
is an optionally substituted aryl, a heteroaryl or the like; R
1
is a hydrogen atom, an alkyl or the like; R
2a
is a substituted cycloaryl, a heterocycloaryl or the like) and a general formula (I):
2
(wherein A, Ar
1
, Ar
2
, and R
1
are the same as defined above and R
2
is an hydrogen atom, R
2a
or the like) and salts thereof, which have TNF-&agr; converting enzyme (TACE) inhibitory activity.
BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-alpha CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES
申请人:Duan Jingwu
公开号:US20070167451A1
公开(公告)日:2007-07-19
The present application describes novel barbituric acid derivatives of formula I:
or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, B, L, R
1
, R
2
, R
3
, R
4
, R
5
, n, W, U, X, Y, Z, U
a
, X
a
, Y
a
, and Z
a
are defined in the present specification, which are useful as TNF-α converting enzyme (TACE) and matrix metalloproteinases (MMP) inhibitors.